Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Lifelong Vigilance: Survivorship and Late Effects of LCH

At a Glance

After LCH treatment, patients enter a survivorship phase focused on monitoring for permanent late effects, such as hormone imbalances, hearing loss, and rare neurological changes. Consistent surveillance helps catch and manage these complications early.

Finishing treatment for LCH is a major milestone, but it is often the start of a new chapter called survivorship. Because LCH is a “chronic” condition, the focus shifts from clearing active lesions to monitoring for permanent consequences (late effects) and ensuring a high quality of life [1][2].

Understanding Permanent Consequences

Even after the LCH cells are gone, they can leave behind “footprints”—changes to the body that are permanent. These are more common in patients who had multisystem disease or lesions in “CNS-risk” areas [3][4].

  • Endocrine Issues: The most common late effect is Central Diabetes Insipidus (CDI), which affects the body’s water balance [5]. Other hormones can also be affected, leading to Growth Hormone Deficiency (slowed growth in children) or thyroid problems [6][7].
  • Hearing Loss: If LCH was present in the bones near the ear, it can cause permanent damage to hearing that may develop or worsen over time [8].
  • Neurological Changes: Some survivors may experience Neurodegenerative LCH (ND-LCH), a rare condition where parts of the brain (like the cerebellum) show signs of stress or damage [9][10].

Monitoring for Neurodegeneration (ND-LCH)

ND-LCH is rare and typically develops very slowly. Early signs can be subtle, such as changes in balance, coordination, or handwriting [11][12].

  • Biomarkers: Researchers now use a blood test called Neurofilament Light (NfL) to monitor for this [13]. NfL is a protein released when nerve cells are under stress. High levels can act as an early warning system, sometimes showing changes before a patient feels any symptoms or an MRI shows a difference [13][14].
  • MRI Surveillance: Specialized brain MRIs are used to look for specific patterns of “white matter” changes or shrinkage (atrophy) in the cerebellum [15][16].

The Surveillance Schedule

Follow-up care is about staying one step ahead of the disease. A typical surveillance plan might include:

  1. Endocrine Screenings: Annual blood tests to check all pituitary hormones [17][7].
  2. Regular Physicals: Checking for an enlarged liver or spleen and monitoring height and weight [6].
  3. Imaging: Periodic scans (like PET or MRI) are common in the first few years after treatment, gradually becoming less frequent as time passes [18][19].

Managing “Scanxiety”

It is completely normal to feel intense anxiety leading up to follow-up appointments—a phenomenon often called scanxiety.

  • Preparation: Ask your team exactly when and how you will receive results so you aren’t left waiting by the phone.
  • Support: Many families and adult patients find it helpful to work with social workers or therapists to help process the stress of routine monitoring [20][21].

Vigilance is the key to survivorship. By staying consistent with follow-up appointments, you ensure that if any “late effects” do appear, they are caught early and managed effectively.

Back to Home

Common questions in this guide

What are the most common late effects after LCH treatment?
The most common permanent consequence is Central Diabetes Insipidus (CDI), which disrupts the body's water balance. Other potential late effects include growth hormone deficiency, thyroid issues, hearing loss, and rare neurological changes.
What is neurodegenerative LCH (ND-LCH)?
ND-LCH is a rare condition where parts of the brain, such as the cerebellum, show signs of stress or damage after active LCH is gone. Early warning signs can be subtle and may include changes in balance, coordination, or handwriting.
Why might my doctor order an NfL blood test?
Neurofilament Light (NfL) is a protein released when nerve cells are stressed. A blood test for NfL can act as an early warning system for neurodegeneration, often detecting issues before you feel symptoms or before they appear on an MRI.
How often will I need follow-up scans after finishing treatment?
Imaging like PET or MRI scans is typically frequent in the first few years following treatment. As time passes and you remain stable, your doctor will likely decrease the frequency of these scans as part of a long-term survivorship plan.
How can I manage my anxiety before follow-up scans?
It is completely normal to feel intense anxiety, often called 'scanxiety', before follow-up appointments. You can help manage this by establishing a clear plan with your doctor on when and how you will get your results, and by seeking support from a therapist or social worker.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific 'late effects' are most at risk based on the original disease locations?
  2. 2.Should testing for the NfL (Neurofilament Light) biomarker be done to screen for early signs of neurodegeneration?
  3. 3.How often do we need to see an endocrinologist to check for growth hormone or thyroid issues?
  4. 4.Is hearing at risk, and is a formal audiological evaluation necessary?
  5. 5.Can we establish a 'survivorship plan' that outlines all necessary scans and blood work for the next five years?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.

    Tazi A, Lorillon G, Haroche J, et al.

    Orphanet journal of rare diseases 2017; (12(1)):95 doi:10.1186/s13023-017-0651-z.

    PMID: 28532436
  2. 2

    Isolated Langerhans cell histiocytosis of the stomach in adults: An analysis of clinicopathologic characteristics and molecular genetics.

    Wu R, Zhao Y, Wu X, et al.

    Medicine 2024; (103(51)):e40950 doi:10.1097/MD.0000000000040950.

    PMID: 39705477
  3. 3

    Late outcomes in children with Langerhans cell histiocytosis.

    Chow TW, Leung WK, Cheng FWT, et al.

    Archives of disease in childhood 2017; (102(9)):830-835 doi:10.1136/archdischild-2016-312185.

    PMID: 28442470
  4. 4

    Long-term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96/02 studies.

    Sakamoto K, Morimoto A, Shioda Y, et al.

    British journal of haematology 2021; (192(3)):615-620 doi:10.1111/bjh.17243.

    PMID: 33236384
  5. 5

    The multiple faces of Langerhans cell histiocytosis in childhood: A gentle reminder.

    Papadopoulou M, Panagopoulou P, Papadopoulou A, et al.

    Molecular and clinical oncology 2018; (8(3)):489-492 doi:10.3892/mco.2017.1539.

    PMID: 29468064
  6. 6

    Neuroendocrine manifestations of Langerhans cell histiocytosis.

    Yavropoulou MP, Tsoli M, Kaltsas G

    Handbook of clinical neurology 2021; (181()):127-135 doi:10.1016/B978-0-12-820683-6.00009-9.

    PMID: 34238452
  7. 7

    Endocrine manifestations in a cohort of 63 adulthood and childhood onset patients with Langerhans cell histiocytosis.

    Sagna Y, Courtillot C, Drabo JY, et al.

    European journal of endocrinology 2019; (181(3)):275-285.

    PMID: 31269469
  8. 8

    A case of bilateral sensorineural hearing loss from Langerhans cell histiocytosis.

    Henderson AH, Khan AA, Good C, Baer ST

    BMJ case reports 2015; (2015()).

    PMID: 26341162
  9. 9

    Neurodegeneration in Langerhans Cell Histiocytosis: beyond a Sequela.

    Santa-María López V, Gutiérrez-Carrasco I, Pérez-Martínez A, et al.

    Anales de pediatria 2026; (104(2)):504058 doi:10.1016/j.anpede.2026.504058.

    PMID: 41651751
  10. 10

    CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.

    McClain KL, Picarsic J, Chakraborty R, et al.

    Cancer 2018; (124(12)):2607-2620 doi:10.1002/cncr.31348.

    PMID: 29624648
  11. 11

    Eye movement abnormalities in neurodegenerative langerhans cell histiocytosis.

    Autier L, Gaymard B, Bayen E, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(11)):6539-6546 doi:10.1007/s10072-022-06180-y.

    PMID: 35760933
  12. 12

    Altered cerebral perfusion in children with Langerhans cell histiocytosis after chemotherapy.

    Han M, Kim LH, Shpanskaya K, et al.

    Pediatric blood & cancer 2020; (67(3)):e28104 doi:10.1002/pbc.28104.

    PMID: 31802628
  13. 13

    New biomarker paves the way for a clinical trial for neurodegeneration in Langerhans cell histiocytosis.

    Shioda Y, Sakamoto K, Morimoto A

    British journal of haematology 2022; (198(4)):623-624 doi:10.1111/bjh.18308.

    PMID: 35727899
  14. 14

    Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome.

    Körtvelyessy P, Kuhle J, Düzel E, et al.

    Annals of clinical and translational neurology 2020; (7(11)):2213-2220 doi:10.1002/acn3.51207.

    PMID: 33030817
  15. 15

    Quantitative Brain MRI Analysis in Neurodegenerative Langerhans Cell Histiocytosis.

    Baek C, de la Rosa LR, Aliouat I, et al.

    European journal of neurology 2025; (32(6)):e70249 doi:10.1111/ene.70249.

    PMID: 40522095
  16. 16

    Early Diagnosis and Monitoring of Neurodegenerative Langerhans Cell Histiocytosis.

    Sieni E, Barba C, Mortilla M, et al.

    PloS one 2015; (10(7)):e0131635 doi:10.1371/journal.pone.0131635.

    PMID: 26176859
  17. 17

    Successful management of multiple-systemic Langerhans cell histiocytosis involving endocrine organs in an adult: A case report and review of literature.

    Xie J, Li Z, Tang Y

    Medicine 2018; (97(26)):e11215 doi:10.1097/MD.0000000000011215.

    PMID: 29952977
  18. 18

    68 Ga-FAPI and 18 F-FDG PET/CT Imaging in Langerhans Cell Histiocytosis for Recurrence and Therapeutic Response Assessment.

    Liu M, Tang R, Chen X, et al.

    Clinical nuclear medicine 2024; (49(11)):1027-1030 doi:10.1097/RLU.0000000000005476.

    PMID: 39325544
  19. 19

    18F-FDG PET/CT in follow-up evaluation in pediatric patients with Langerhans histiocytosis.

    Garcia JR, Riera E, Bassa P, et al.

    Revista espanola de medicina nuclear e imagen molecular 2017; (36(5)):325-328 doi:10.1016/j.remn.2017.01.007.

    PMID: 28262495
  20. 20

    Dissemination of an evidence-based behavioral intervention to alleviate distress in caregivers of children recently diagnosed with cancer: Bright IDEAS.

    Voll M, Fairclough DL, Morrato EH, et al.

    Pediatric blood & cancer 2022; (69(10)):e29904 doi:10.1002/pbc.29904.

    PMID: 35929012
  21. 21

    The multidisciplinary pediatric psycho-oncology workforce: A national report on supervision for staff and training opportunities.

    Kazak AE, Scialla MA, Patenaude AF, et al.

    Psycho-oncology 2018; (27(12)):2802-2808 doi:10.1002/pon.4892.

    PMID: 30242934

This page provides educational information on LCH survivorship and late effects. Always consult your oncologist and endocrinologist to develop a personalized, long-term follow-up care plan.

Get notified when new evidence is published on Langerhans cell histiocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.